Kim Dongmin, Lee Jieun, Kang Jun, Kim Sung Hun, Yoo Tae-Kyung, Oh Sooeun, Lee Ahwon
Department of Hospital Pathology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Department of Biomedicine & Health Sciences, College of Medicine, The Catholic University of Korea, Seoul, Korea.
J Breast Cancer. 2019 Dec;22(4):562-578. doi: 10.4048/jbc.2019.22.e56.
Triple-negative breast cancer (TNBC) is associated with poor prognosis with limited treatment options. Angiogenesis is known to be involved in the progression of TNBC, and targeting this pathway results in modest clinical benefits. In this study, we analyzed the role of tumor microvascular endothelial Notch1 (EC Notch1) and tumoral miR-34a as prognostic markers in patients with TNBC.
The expression of miR-34a was analyzed using archival tumor tissues from 114 patients with TNBC. Simultaneously, archival tumor tissues were also checked for the expression of CD34 and Notch1 by immunostaining. The ratio of Notch1-microvascular density (MVD) to CD34-MVD was defined as EC Notch1. The association between the expression of miR-34a or EC Notch1 and clinicopathological characteristics was analyzed.
In the overall patient population, patients with low expression of EC Notch1 was associated with better overall survival (OS, = 0.041) than those with high expression of EC Notch1. In lymph node-positive TNBC patients, high levels of miR-34a and low levels of EC Notch1 correlated significantly with higher survival benefits in terms of OS ( = 0.026), disease-free survival ( = 0.009), and metastasis-free survival ( = 0.038) relative to that in other patients. Decreased expression of EC Notch1 and increased expression of miR-34a also showed a survival benefit in locally advanced TNBC.
The fact that miR-34a and EC Notch1 are associated with the angiogenesis suggests that angiogenesis may play a role in the development and progression of TNBC.
三阴性乳腺癌(TNBC)预后较差,治疗选择有限。已知血管生成参与TNBC的进展,靶向该途径可带来一定的临床益处。在本研究中,我们分析了肿瘤微血管内皮Notch1(EC Notch1)和肿瘤性miR-34a作为TNBC患者预后标志物的作用。
使用114例TNBC患者的存档肿瘤组织分析miR-34a的表达。同时,通过免疫染色检查存档肿瘤组织中CD34和Notch1的表达。Notch1微血管密度(MVD)与CD34-MVD的比值定义为EC Notch1。分析miR-34a或EC Notch1的表达与临床病理特征之间的关联。
在总体患者人群中,EC Notch1低表达的患者总生存期(OS,=0.041)优于EC Notch1高表达的患者。在淋巴结阳性的TNBC患者中,相对于其他患者,高水平的miR-34a和低水平的EC Notch1在OS(=0.026)、无病生存期(=0.009)和无转移生存期(=0.038)方面与更高的生存获益显著相关。EC Notch1表达降低和miR-34a表达增加在局部晚期TNBC中也显示出生存获益。
miR-34a和EC Notch1与血管生成相关这一事实表明,血管生成可能在TNBC的发生和发展中起作用。